Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on April 15, 2014. The report details corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO). Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and structural changes to the Company's charter and bylaws rather than financial performance.
Material Changes
On April 15, 2014, the Company filed a Restated Certificate of Incorporation and Amended and Restated By-Laws with the State of Delaware. Key changes include:
- Capital Structure: Reduced authorized common stock to 125,000,000 shares; eliminated all references to previously existing preferred stock; authorized 5,000,000 shares of undesignated preferred stock.
- Board Structure: Established a classified board of directors divided into three classes with staggered three-year terms.
- Director Removal: Directors may now be removed only for cause and only upon the affirmative vote of holders of at least 75% of the votes entitled to be cast.
- Stockholder Action: Eliminated the ability of stockholders to take action by written consent in lieu of a meeting.
- Procedures: Established new procedures for stockholder proposals and director nominations.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific business risks. The primary contingency noted is the effectiveness of these amendments upon the closing of the IPO.
Key Facts for Investor Verification
- Verify the exact closing date and terms of the IPO referenced in this filing.
- Confirm the current authorized share count (125,000,000 common; 5,000,000 preferred).
- Review the implications of the classified board structure and the 75% supermajority requirement for director removal on future corporate control.
- Check subsequent filings for the issuance of any new series of preferred stock.